Generic placeholder image

Clinical Cancer Drugs

Editor-in-Chief

ISSN (Print): 2212-697X
ISSN (Online): 2212-6988

Research Article

Weight Gain and Loss in Cancer Patients Undergoing Chemotherapy: Importance of Dose Adjustment

Author(s): Maria Ayanny de Lima Fernandes*, Andreza Tallyne de Aguiar Silva, Iago Dillion Lima Cavalcanti*, Adrya Lúcia Peres Bezerra de Medeiros, Lígia Maria de Oliveira Lima and Tâmara Kelly de Castro Gomes

Volume 8, Issue 2, 2021

Published on: 21 December, 2021

Article ID: e101221198738 Pages: 6

DOI: 10.2174/2212697X08666211210105329

Price: $65

Abstract

Introduction: The established dose of chemotherapy is based on the values of the patient's body weight, where variations during treatment can increase the toxicity of chemotherapy, with the development of nephrotoxicity, among other toxicity profiles, as well as in cases of weight gain, patients may receive low doses and compromise the therapeutic response to the tumor. < p>Objective: To evaluate weight gain and loss in cancer patients undergoing chemotherapy.

Methods: Longitudinal analytical study with patients at the end of chemotherapy treatment of both genders. The type, location of the tumor and the antineoplastic agent used were collected from the medical records, as well as height and weight at the beginning of treatment. At the time of collection, anthropometric assessment was performed using body mass index, arm circumference, arm muscle circumference, triceps skinfold thickness and percentage of weight loss.

Results: Among the patients included in the study, 47.5% had a weight gain of around 2.5 kg, while the remaining patients (52.5%) had a weight loss of around 2.8 kg. Of the patients who had GFR, 55.5% had severe PP, 33.4% had no significant loss and 11.1 had significant loss. In the current study, only 22% had a GFR <60ml/min/1.73m2, but they would already need to readjust the medication calculation.

Conclusion: It is important to evaluate body surface variations and also the GFR to adjust the dose of the antineoplastic agent and to prevent or minimize nephrotoxicity, as well as to reduce the risk of underdosing and inefficiency of the therapy.

Keywords: Weight gain and loss, toxicity, chemotherapy, cancer, nutritional status, BMI.

Graphical Abstract
[1]
Borges LR, Paiva SI, Silveira DH, Assunção MCF, Gonzalez MC. Can nutritional status influence the quality of life of cancer patients? Rev Nutr 2010; 23(5): 745-53.
[http://dx.doi.org/10.1590/S1415-52732010000500005]
[2]
Ferreira D, Guimarães TG, Marcadenti A. Acceptance of hospital diets and nutritional status among inpatients with cancer. Einstein 2013; 11(1): 41-6.
[http://dx.doi.org/10.1590/S1679-45082013000100008] [PMID: 23579742]
[3]
Guimarães RCR, Gonçalves RPF, Lima CA, Torres MR, Silva CSO. Nursing actions facting reactions to chemotherapy in oncological patients. J. res. Fundam Care 2015; 7(2): 2440-52.
[4]
Ferioli M, Zauli G, Martelli AM, et al. Impact of physical exercise in cancer survivors during and after antineoplastic treatments. Oncotarget 2018; 9(17): 14005-34.
[http://dx.doi.org/10.18632/oncotarget.24456] [PMID: 29568412]
[5]
Costa LJM, Varella PCS, del Giglio A. Weight changes during chemotherapy for breast cancer. Sao Paulo Med J 2002; 120(4): 113-7.
[http://dx.doi.org/10.1590/S1516-31802002000400005] [PMID: 12436158]
[6]
Dong S, Wang Z, Shen K, Chen X. Metabolic syndrome and breast cancer: prevalence, treatment response, and prognosis. Front Oncol 2021; 11: 629666.
[http://dx.doi.org/10.3389/fonc.2021.629666] [PMID: 33842335]
[7]
Janus N, Launay-Vacher V, Byloos E, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 2010; 103(12): 1815-21.
[http://dx.doi.org/10.1038/sj.bjc.6605979] [PMID: 21063408]
[8]
Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. ESMO Open 2016; 1(4): e000091.
[http://dx.doi.org/10.1136/esmoopen-2016-000091] [PMID: 27843635]
[9]
Kirjner A, Pinheiro RL. Interferência da Obesidade no Tratamento Quimioterápico em Mulheres com Câncer de Mama. Rev Bras Cancerol 2007; 53(3): 345-54.
[http://dx.doi.org/10.32635/2176-9745.RBC.2007v53n3.1802]
[10]
WHO Expert Committee on Physical Status. WHO Expert Committee on Physical Status: the use and interpretation of Anthropometry.Technical report series. Geneva: World Health Organization 1995; 854: p. 452.
[11]
Frisancho AR. Anthropometric standards for the assessment of growth and nutritional status. Ann Arbor: University of Michigan Press 1990; 189.
[http://dx.doi.org/10.3998/mpub.12198]
[12]
Blackburn GL, Bistrian BR, Maini BS, Schlamm HT, Smith MF. Nutritional and metabolic assessment of the hospitalized patient. JPEN J Parenter Enteral Nutr 1977; 1(1): 11-22.
[http://dx.doi.org/10.1177/014860717700100101] [PMID: 98649]
[13]
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2): S1-S266.
[PMID: 11904577]
[14]
National Cancer Institute (INCA).. Estimate of cancer incidence in Brazil for the 2016-2017 biennium. Avaialble from:http://www.inca.gov.br/wcm/dncc/2015/por-incidencia.asp( Accessed on: July 10, 2020.)
[15]
Santos AF, Lima FRS, Maciel MG, et al. Avaliação nutricional de pacientes com câncer gástrico e de outras localizações. Rev Pesq Saúde 2017; 18(1): 24-7.
[16]
Miranda TV, Neves FMG, Costa GNF, Souza MAM. Estado nutricional e qualidade de vida de pacientes em tratamento quimioterápico. Rev Bras Cancerol 2013; 59(1): 57-64.
[http://dx.doi.org/10.32635/2176-9745.RBC.2013v59n1.544]
[17]
Souza RG, Lopes TVC, Pereira SS, Soares LP, Pena GG. Assessment of nutritional status, food consumption and fuctional capacity in oncologic patients. Braz J Oncol 2017; 13(44): 1-11.
[18]
Cronemberger IF, Luz MCL, Pena LSP, Rocha IMG, Souza LA. Associação do (Asociación entre el) estado nutricional com a qualidade (y la calidad) de vida de pacientes oncológicos em tratamento quimioterápico. Salud(i). Ciencia 2016; 22: 132-9.
[19]
Sampaio HAC, Oliveira NM, Sabry MOD, Carioca AAF, Pinheiro LGP. Influência do tipo de terapia antineoplásica sobre marcadores antropométricos e dietéticos em mulheres portadoras de câncer de mama. Rev Bras Cancerol 2012; 58(2): 223-30.
[http://dx.doi.org/10.32635/2176-9745.RBC.2012v58n2.622]
[20]
Verde SMML. Impacto do tratamento quimioterápico no estado nutricional e no comportamento alimentar de pacientes com neoplasia mamária e suas consequências na qualidade de vida [dissertation p. 138. São Paulo: Universidade de São Paulo. 2007.
[21]
Mendes ESR, Giglio LAGAD, Marucci MFN. Efeitos colaterais da quimioterapia adjuvante sobre o peso corporal de mulheres com câncer de mama. RBM Revista Brasileira de Medicina 2011; 68 (Especial Oncologia):13-18.
[22]
Atalay C, Küçük AI. The impact of weight gain during adjuvant chemotherapy on survival in breast cancer. Ulus Cerrahi Derg 2015; 31(3): 124-7.
[PMID: 26504414]
[23]
Rocha SR, Marques CAV. Functional capacity of women with breast neoplasm undergoing palliative chemotherapy. Revista da Escola de Enfermagem da USP 2021; 55: e03714.
[24]
Jung HW, Kim JW, Kim JY, et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 2015; 23(3): 687-94.
[http://dx.doi.org/10.1007/s00520-014-2418-6] [PMID: 25163434]
[25]
Vega MC, Laviano A, Pimentel GD. Sarcopenia and chemotherapy-mediated toxicity. Einstein 2016; 14(4): 580-4.
[http://dx.doi.org/10.1590/s1679-45082016md3740] [PMID: 28076611]
[26]
Silva JM, Silva LV, Preta RTOC. Modelagem Matemática da Quimioterapia Um estudo da qualidade de vida do paciente. Revista Científica Vozes dos Vales – UFVJM 2016; 10: 1-13.
[27]
Launay-Vacher V, Spano JP, Janus N, et al. Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 2009; 70(2): 124-33.
[http://dx.doi.org/10.1016/j.critrevonc.2008.09.012] [PMID: 18990585]
[28]
Almeida SMV, Alcantara FF, Brito CGX, Souza GCA, Lafayette EA, et al. Compostos coordenados híbridos de platina no tratamento do câncer. Rev Cienc Farm Basica Apl 2014; 35(3): 337-45.
[29]
Berns JS, Ford PA. Renal toxicities of antineoplastic drugs and bone marrow transplantation. Semin Nephrol 1997; 17(1): 54-66.
[PMID: 9000550]
[30]
Sato K, Watanabe S, Ohtsubo A, et al. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer 2016; 16: 222.
[http://dx.doi.org/10.1186/s12885-016-2271-8] [PMID: 26979596]
[31]
dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 2012; 86(8): 1233-50.
[http://dx.doi.org/10.1007/s00204-012-0821-7] [PMID: 22382776]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy